Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
QSAR Lab is a private Polish computational chemistry and digital toxicology company that provides in silico R&D and regulatory-support services for chemicals, nanomaterials, peptides, and related life-science applications. The company uses QSAR/QSPR modeling, read-across, machine learning, and AI to design safer chemicals and advanced materials, predict toxicological and physicochemical properties, and support REACH- and OECD-aligned risk assessment workflows. Its offerings span digital design of chemicals and nanomaterials, digital toxicity assessment, AI/ML data analysis, training, and R&D consulting. QSAR Lab also develops software and data platforms including PredMat for nanomaterials, PeptAIm for peptide design, PredSuite for ready-to-use predictive models, and NAMs.network for New Approach Methodologies resources. The company appears to operate primarily as a services and platform business rather than a therapeutic drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on QSAR Lab.